In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based

In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)

The process of drug development, beginning from the discovery of a pharmacological lead to its commercial launch, is estimated to take around 10-15 years, involving capital investments in the range of USD 4-10 billion. , Moreover, it is well-known that only a small proportion of leads, which are selected for further investigation during the initial stages of research, are actually translated into product candidates for clinical research studies. Over time, the complexities of drug discovery, have increased; this is especially true for large molecules, which are inherently more complex than conventional small molecule drugs. As a result, there has been a direct rise in overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector. Specifically, in 2019, the global R&D spending was estimated to be around USD 182 billion, with over 16,000 drug molecules reported to have been investigated. Presently, the industry is currently under tremendous pressure to identify ways to cope with rising capital requirements in drug discovery research and actively avoid losses owing to failed drug development programs. In addition, there has been an evident increase in regulatory stringency, which has made the drug approval process, especially for large molecules, significantly more difficult.

During the last several years, several computational tools have been developed and introduced for enabling the identification, selection and optimization of pharmacological lead candidates. Currently, there are several in silico approaches available for the drug discovery process alone, such as structure based drug design, fragment based drug discovery and ligand based drug discovery. The predictive power of these in silico tools has been proven to be very advantageous, allowing researchers to bypass the random screening of billions of molecules across hundreds of large molecule targets. According to industry experts, almost 35% of the total cost and time invested in developing a new drug can be saved by adopting an in silico approach. As a result, companies offering in silico drug discovery services, such as computer-aided drug design (CADD), molecular modeling and quantitative structure–activity relationship (QSAR), have now become an important part of the pharmaceutical industry. In future, drug developers, especially those focused on the development of large molecules, are likely to continue relying on outsourcing for a significant part of their respective drug discovery and development operations.

The “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)” report features an extensive study on the current landscape and the likely future potential of the companies offering services for the discovery of large molecule drugs based on the use of in silico tools and techniques. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders. In addition to other elements, the report includes:
A detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules, including information on year of establishment, company size, location of headquarters, type of business model used (contract service providers (CROs), software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, antibody drug conjugates (ADCs), antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors and nucleic acids), type of in silico approach used (structure-based drug design (SBDD), fragment-based drug design (FBDD), target-based drug design (TBDD), ligand-based drug design (LBDD) and interface-based drug design (IBDD)), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes).
Insights on contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of location of their company size (small (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.
Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services, featuring a brief overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio) and an informed future outlook.
A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters, such as the experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.
An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services offered and number of large molecules, for which the aforementioned services are offered.
A detailed analysis assessing the current opportunity within in silico drug discovery services market, comparing the number of pipeline products and current market size across different types of large molecules, and the availability and capabilities of affiliated in silico drug discovery service providers.
A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.
An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.
A case study comparing the key challenges associated with the discovery and production of large molecules, affiliated product development timelines, and manufacturing protocols, with those of small molecule drugs.
Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in providing in silico services for discovery of large molecule drugs.
A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery purposes and are likely to impact early stage research over the coming years.
A case study highlighting several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.

One of the key objectives of this report was to understand the primary growth drivers and estimate the future size of the in silico drug discovery services market. Based on several parameters, such as number of large molecules based drug discovery projects, adoption of in silico services for drug discovery and outsourcing profile, we have provided informed estimates on the likely evolution of the market for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] key step(s) of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization), [B] type of large molecule (antibodies, proteins, peptides, nucleic acids and vectors), [C] company size (small, mid-sized and large), [D] therapeutic area (autoimmune disorders, blood disorders, cardiovascular disorders, gastrointestinal and digestive disorders, hormonal disorders, HIV / AIDS, infectious diseases, metabolic disorders, mental disorders, musculoskeletal disorders, neurological disorders, oncological disorders, respiratory disorders, skin disorders, urogenital disorders and others), [E] type of clientele (pharmaceutical / biotechnology companies and academic / research institutes), and [F] key geographical regions (North America (the US and Canada), Europe (Italy, Germany, France, Spain and rest of Europe) and Asia-Pacific (China, India and Japan), along with the rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this report were also influenced by inputs solicited via a survey and discussions held with senior stakeholders in the industry. The report features detailed transcripts of discussions held with the following individuals (in alphabetical order):
John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point)
Sven Benson (Founder, candidum)
Mark Whittaker (Senior Vice President, Evotec)
Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the in silico services market and its likely evolution in the short-mid term and long term.

Chapter 3 provides an introduction to the overall drug discovery process, including details on the time taken for a drug to traverse from the bench to the market, and the various stages of the drug discovery process. It also provides an overview of various in silico drug discovery approaches, and a detailed classification of computer-aided research tools and techniques. In addition, it features information on the applications of in silico tools across different steps of the drug discovery process, along with details of specific in silico methods / approaches associated with these steps. It also highlights the benefits of the in silico approach and the key challenges associated with carrying out in silico (including CADD) drug discovery research in-house. Finally, the chapter highlights the current preference to outsource such operations, especially for large molecule drugs.

Chapter 4 provides an assessment of the global landscape of the in silico services market. It includes information on over 60 players that are currently engaged in providing such services for discovery of large molecules. It features an in-depth market overview, including information on location of headquarters, employee count, type of business model used (contract service providers, software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, ADCs, antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors, nucleic acids), type of in silico approach used (SBDD, FBDD, TBDD, LBDD and IBDD), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes). It also includes the list of various software tools / web applications / technology platforms offered by the in silico service providers for the drug discovery, has been provided.

Chapter 5 presents a compilation of the key insights generated from the study highlighting the contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of the location of their company size (small-sized (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.

Chapter 6 features detailed profiles of key industry in silico drug discovery service providers, which were established after 2000 and have an employee base of more than 500 individuals. Each profile provides an overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio, and an informed future outlook. In addition, each profile features a peer group-based benchmark comparison matrix for the players based on several parameters, such as experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.

Chapter 7 features an insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services and number of large molecules for which the aforementioned services are offered.

Chapter 8 presents the detailed analysis assessing the current opportunity within in silico drug discovery services market, along with the comparison of the number of pipeline products and current market size across different types of large molecules and the availability and capabilities of affiliated in silico drug discovery service providers.

Chapter 9 features the various business strategies that can be adopted by in silico service providers for maintaining the competitive edge in the industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.

Chapter 10 presents the comparison of the challenges associated with the discovery and production of large molecules, comparing affiliated product development timelines, and manufacturing protocols with those of small molecule drugs. In addition, several approaches have been highlighted, which can be incorporated to overcome the challenges in the drug discovery of large molecules.

Chapter 11 presents insights generated from an industry-wide survey, wherein we had approached nearly 100 stakeholders involved in outsourcing in silico services. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.

Chapter 12 presents a comprehensive analysis of the cost saving potential associated with the use of in silico services in the drug discovery process for large molecules.

Chapter 13 presents a comprehensive market forecast analysis, highlighting the future potential of the in silico drug discovery services market till the year 2030. It features the likely distribution of the market based on [A] key step(s) of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization), [B] type of large molecule (antibodies, proteins, peptides, nucleic acids and vectors), [C] company size (small-sized, mid-sized and large), [D] therapeutic areas (autoimmune disorders, blood disorders, cardiovascular disorders, gastrointestinal and digestive disorders, hormonal disorders, HIV / AIDS, infectious diseases, metabolic disorders, mental disorders, musculoskeletal disorders, neurological disorders, oncological disorders, respiratory disorders, skin disorders, urogenital disorders and others), [E] type of clientele (pharmaceutical / biotechnology companies and academic / research institutes), and [F] key geographical regions (North America (the US and Canada), Europe (Italy, Germany, France, Spain and rest of Europe), and Asia-Pacific (China, India and Japan), along with the rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 14 provides a brief overview of the upcoming computational technologies, which are being developed to deal with the innate complexities associated with the process of drug discovery and optimize the overall time spent on early stage research.

Chapter 15 is a collection of interview transcripts of discussions held with key stakeholders in this industry. In this chapter, we have presented the details of our conversations held with John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals), Sven Benson (Founder, candidum), Mark Whittaker (Senior Vice President, Evotec) and Edelmiro Moman (Scientific Consultant and Teacher, ProSciens).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which provides the list of companies and organizations mentioned in the report.

Chapter 18 is an appendix, which features a detailed discussion of several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 16S Technologies
2. Ab Studio
3. AbbVie
4. AbCheck
5. Abzena
6. Adagio Pharmaceuticals
7. Adimab
8. Advent International
9. Ajinomoto Bio-Pharma
10. Allesh Biosciences Labs
11. Allosterix Pharmaceuticals
12. Ambrx
13. AMRI
14. Antitope (acquired by Abzena)
15. Antiverse
16. ApconiX
17. Aprecia Pharmaceuticals
18. Aptuit
19. AsiaVest Partners
20. AstraZeneca
21. ATHOS Service
22. Avistron Chemistry Services
23. Bayer Animal Health
24. BDG LifeSciences
25. BenevolentAI
26. Berkeley Lights
27. Betta Biomedical Industry Fund
28. BIANA
29. Bill & Melinda Gates Foundation
30. BioAscent
31. BioBench Solutions
32. Bioclinica
33. BioDuro
34. BioGlobal Consulting Group
35. BioNTech
36. Biotech Investment Group
37. BIOTEM
38. BMG LABTECH
39. Broad Institute of MIT and Harvard
40. BVCF Management
41. Caldan Therapeutics
42. CALIXAR
43. candidum
44. CardioVascular Research Foundation
45. CARLBio
46. Catalent Pharma Solutions
47. CELLSCRIPT
48. Charles River Laboratories
49. ChemBio Discovery Solutions
50. ChemBridge
51. ChemDiv
52. ChemoGenics BioPharma
53. ChemPartner
54. Cloud Pharmaceuticals
55. CompChem Solutions
56. Concept Life Sciences
57. Conifer Point
58. Conifer Point Pharmaceuticals
59. Creative Biolabs
60. Creative Biostructure
61. Creative Diagnostics
62. Cyclica
63. Cyprotex
64. Defense Advanced Research Projects Agency
65. Domainex
66. DuPont
67. Eli Lilly
68. European Investment Bank
69. Evotec
70. Fidelity Management & Research
71. Fidelta (a CRO Subsidiary of Galapagos)
72. Formex
73. Fractal Therapeutics
74. Fusion Antibodies
75. Genedata Biologics
76. Genentech
77. Genevant Sciences
78. Genmab
79. Genomodel
80. GenScript
81. Gfree Bio
82. Greenpharma
83. Harlan Laboratories
84. Harvard University
85. HiFiBiO
86. HQL Pharmaceuticals
87. IBM Watson
88. Icagen
89. ICON
90. IDG Capital
91. ImmunoPrecise Antibodies
92. In-Cell-Art
93. Insilico Medicine
94. Inte:Ligand
95. Integral Molecular
96. Invus
97. IRBM
98. Ironwood Pharmaceuticals
99. IXTAL
100. Janssen
101. Janus Henderson Investors
102. Jebsen Capital
103. JPT Peptide Technologies
104. Jubilant Biosys
105. Keapstone Therapeutics
106. LakePharma
107. Lead Discovery Center
108. LeadInvent Technologies
109. Life Technologies
110. MabVax Therapeutics
111. Mascot Industries
112. Merck
113. Metropolis Healthcare
114. Micar Innovation
115. MIG Funds
116. Mind the Byte
117. Mirae Asset
118. Molecular Devices
119. Molecular Forecaster
120. Molecular Response
121. Moleculomics
122. Molsoft
123. N2 Business Growth Fund
124. NIH
125. NovaData Solutions
126. NovAliX
127. Novartis
128. Novo Informatics
129. NuChem Therapeutics
130. Numerate
131. NYU Langone Health
132. Oscotec
133. PacificGMP
134. Patheon
135. Pathios Therapeutics
136. Peak Proteins
137. Pelago Bioscience
138. Pepscan
139. Peptone
140. Pfizer
141. Pharma Inventor
142. Pharmacelera
143. Pharmacia
144. Phoenix Equity Partners
145. Platinum Asset Management
146. PolyTherics (acquired by Abzena)
147. Porton Pharma Solutions
148. PPD
149. Prestwick Chemical (acquired by Bionomics)
150. Profacgen
151. ProMab Biotechnologies
152. Prosarix
153. ProteinQure
154. ProteoGenix
155. Provid Pharmaceuticals
156. PX'Therapeutics
157. QIAGEN
158. Quantitative Medicine
159. RASA Life Science Informatics
160. Redmile Group
161. RedX Pharma
162. Roche
163. Rosa
164. Rosetta Design Group
165. RuiYi
166. Sai Life Sciences
167. Sandexis
168. Sandoz
169. Sanofi
170. Schering Plough
171. Schrödinger
172. Shuwen Biotech
173. SilcsBio
174. Sitryx
175. Sonnet BioTherapeutics
176. Sosei Heptares
177. Steam Athena Capital
178. Struengmann Family Office
179. Sundia MediTech
180. Sygnature Discovery
181. Syngene
182. Taros Chemicals
183. Telix Pharmaceuticals
184. The Chemistry Research Solution (acquired by Abzena)
185. Tmunity Therapeutics
186. TRIANNI
187. University of Pennsylvania
188. UPM
189. Viramatix
190. Virtua Drug
191. Viva Biotech
192. Viva Vision
193. Warwick Effect Polymers
194. WuXi AppTec
195. Wyss Institute
196. YUMAB
197. ZoBio
198. Zorilla Research


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Discovery and Development Timelines
3.3. Overview of In Silico Drug Discovery Tools
3.3.1. Historical Evolution of the In Silico Approach
3.3.2. Comparison of Traditional Drug Discovery Approaches and In Silico / Computer Aided Methods
3.3.3. In Silico / Computed Aided Approaches for Drug Design and Development
3.4. Applications of In Silico Tools in the Drug Discovery Process
3.4.1. Target Identification
3.4.1.1. Chemoinformatics-based Tools
3.4.1.2. Network-based Drug Discovery
3.4.1.3. Computational Platforms and Interaction Repositories
3.4.2. Target Validation
3.4.3. Hit Generation
3.4.3.1. High-Throughput Screening
3.4.3.2. Fragment Based Screening
3.4.3.3. Virtual Screening
3.4.4. Hit-to-Lead
3.4.4.1. Pharmacodynamics and Pharmacokinetics Modeling
3.4.4.2. Other Novel Approaches
3.4.5. Lead Optimization
3.4.5.1. Pharmacophore Modeling
3.4.5.2. Docking
3.4.5.3. Structure Activity Relationships (SAR) / Quantitative Structure Activity Relationship (QSAR)
3.4.5.4. Molecular Modeling
3.5. Advantages of using In Silico Tools for Drug Discovery
3.6. Challenges Associated with Conducting In Silico Drug Discovery Operations In-house
3.7. Anticipated Rise in Outsourcing In Silico Drug Discovery Operations
3.8. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. In Silico Drug Discovery Services for Large Molecules: List of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Business Model
4.2.6. Analysis by Drug Discovery Steps
4.2.7. Analysis by Type of Large Molecule
4.2.7.1. Analysis by Type of Antibody
4.2.7.2. Analysis by Type of Protein
4.2.8. Analysis by Type of In Silico Approach Used
4.2.9. Analysis by Types of In Silico Services Offered
4.2.10. Analysis by Type of Clientele
4.3. In Silico Drug Discovery Services: List of Software / Technologies
4.4. In Silico Drug Discovery Services: List of Consulting and Training Service Providers
5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Logo Landscape: Analysis by Company Size and Location of Headquarters
5.3. Tree Map Representation: Analysis by Company Size and Drug Discovery Steps
5.4. World Map Representation: Regional Analysis of Outsourcing Activity
5.5. Grid Representation: Analysis by Type of Large Molecule, In Silico Approach Used and Type of Clientele
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Leading Players Based in North America
6.2.1. BioDuro
6.2.1.1. Company Overview
6.2.1.2. Funding and Investment Information
6.2.1.3. In Silico-based Service Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.1.5. Company Benchmarking Output
6.2.2. Creative Biostructure
6.2.2.1. Company Overview
6.2.2.2. Funding and Investment Information
6.2.2.3. In Silico-based Service Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.2.5. Company Benchmarking Output
6.2.3. GenScript
6.2.3.1. Company Overview
6.2.3.2. Funding and Investment Information
6.2.3.3. In Silico-based Service Portfolio
6.2.3.4. Recent Developments and Future Outlook
6.2.3.5. Company Benchmarking Output
6.2.4. LakePharma
6.2.4.1. Company Overview
6.2.4.2. Funding and Investment Information
6.2.4.3. In Silico-based Service Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.2.4.5. Company Benchmarking Output
6.3. Leading Players Based in Europe
6.3.1. Abzena
6.3.1.1. Company Overview
6.3.1.2. Funding and Investment Information
6.3.1.3. In Silico-based Service Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.1.5. Company Benchmarking Output
6.3.2. BioNTech
6.3.2.1. Company Overview
6.3.2.2. Funding and Investment Information
6.3.2.3. In Silico-based Service Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.2.5. Company Benchmarking Output
6.3.3. Sygnature Discovery
6.3.3.1. Company Overview
6.3.3.2. Funding and Investment Information
6.3.3.3. In Silico-based Service Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.3.3.5. Company Benchmarking Output
6.4. Leading Players Based in Asia-Pacific
6.4.1. ChemPartner
6.4.1.1. Company Overview
6.4.1.2. In Silico-based Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.1.4. Company Benchmarking Output
6.4.2. Sundia MediTech
6.4.2.1. Company Overview
6.4.2.2. Funding and Investment Information
6.4.2.3. In Silico-based Service Portfolio
6.4.2.4. Recent Development and Future Outlook
6.4.2.5. Company Benchmarking Output
6.4.3. Viva Biotech
6.4.3.1. Company Overview
6.4.3.2. Funding and Investment Information
6.4.3.3. In Silico-based Service Portfolio
6.4.3.4. Recent Development and Future Outlook
6.4.3.5. Company Benchmarking Output
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Assumptions and Methodology
7.3. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
7.4. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
7.5. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World
8. KEY OPPORTUNITY AREAS
8.1. Chapter Overview
8.2. Key Assumptions and Methodology
8.3. Antibodies
8.3.1. Developer Landscape
8.3.1.1. Number of Pipeline Molecules
8.3.1.2. Affiliated Market Size and Growth Rate
8.3.2. In Silico Service Providers for Antibodies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.4. Cell Therapies
8.4.1 Developer Landscape
8.4.1.1 Number of Pipeline Molecules
8.4.1.2 Affiliated Market Size and Growth Rate
8.4.2. In Silico Service Providers for Cell Therapies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.5. Gene Therapies
8.5.1 Developer Landscape
8.5.1.1 Number of Pipeline Molecules
8.5.1.2 Affiliated Market Size and Growth Rate
8.5.2. In Silico Service Providers for Gene Therapies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.6. Nucleic Acids
8.6.1 Developer Landscape
8.6.1.1 Number of Pipeline Molecules
8.6.1.2 Affiliated Market Size and Growth Rate
8.6.2. In Silico Service Providers for Nucleic Acids: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.7. Peptides
8.7.1. Developer Landscape
8.7.1.1. Number of Pipeline Molecules
8.7.1.2. Affiliated Market Size and Growth Rate
8.7.2. In Silico Service Providers for Peptides: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.8. Proteins
8.8.1. Developer Landscape
8.8.1.1. Number of Pipeline Molecules
8.8.1.2. Affiliated Market Size and Growth Rate
8.8.2. In Silico Service Providers for Proteins: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
8.9. Vectors
8.9.1 Developer Landscape
8.9.1.1 Number of Pipeline Molecules
8.9.1.2 Affiliated Market Size and Growth Rate
8.9.2. In Silico Service Providers for Vectors: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
9. EMERGING BUSINESS MODELS AND STRATEGIES
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. In Silico Service Providers: Analysis by Number of Large Molecules and Drug Discovery Steps Covered
9.3.1. Strategies for Short Term Success
9.3.2. Strategies for Long Term Success
9.4. Concluding Remarks
10. CASE STUDY: COMPARISON OF DRUG DISCOVERY PROCESSES OF SMALL MOLECULES AND LARGE MOLECULES
10.1. Chapter Overview
10.2. Small Molecule and Large Molecule Drugs
10.2.1. Comparison of Key Specifications
10.2.2. Comparison of Manufacturing Processes
10.2.3. Comparison of Drug Discovery Processes
10.3. Approaches to Improve Discovery Process of Large Molecules
11. SURVEY ANALYSIS
11.1. Chapter Overview
11.2. Overview of Respondents
11.2.1. Seniority Level of Respondents
11.3. Survey Insights
11.3.1. Drug Discovery Steps
11.3.2. Type of Large Molecules
11.3.3. In Silico Service Portfolio
11.3.4. Likely Adoption of In Silico Tools for Large Molecules Drug Discovery
11.3.5. Current Market Opportunity
11.3.6. Cost Saving Potential of the In Silico Approach
12. COST SAVING ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions
12.3. Scope and Methodology
12.4. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, 2020-2030
12.5. Concluding Remarks
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall In Silico Drug Discovery Services Market for Large Molecules, 2020-2030
13.3.1. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, 2020-2030
13.3.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Identification, 2020-2030
13.3.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Validation, 2020-2030
13.3.1.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit Generation, 2020-2030
13.3.1.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit-to-Lead, 2020-2030
13.3.1.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Lead Optimization, 2020-2030
13.3.2. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, 2020-2030
13.3.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Antibodies, 2020-2030
13.3.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Proteins, 2020-2030
13.3.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Peptides, 2020-2030
13.3.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Nucleic Acids, 2020-2030
13.3.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Vectors, 2020-2030
13.3.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, 2020-2030
13.3.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Small Companies, 2020-2030
13.3.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Mid-sized Companies, 2020-2030
13.3.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Large Companies, 2020-2030
13.3.4. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Therapeutic Area, 2020-2030
13.3.4.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Autoimmune Disorders, 2020-2030
13.3.4.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Blood Disorders, 2020-2030
13.3.4.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Cardiovascular Disorders, 2020-2030
13.3.4.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Gastrointestinal and Digestive Disorders, 2020-2030
13.3.4.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Hormonal Disorders, 2020-2030
13.3.4.6. In Silico Drug Discovery Services Market for Large Molecules: Share of Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS), 2020-2030
13.3.4.7. In Silico Drug Discovery Services Market for Large Molecules: Share of Infectious Diseases, 2020-2030
13.3.4.8. In Silico Drug Discovery Services Market for Large Molecules: Share of Metabolic Disorders, 2020-2030
13.3.4.9. In Silico Drug Discovery Services Market for Large Molecules: Share of Mental Disorders, 2020-2030
13.3.4.10. In Silico Drug Discovery Services Market for Large Molecules: Share of Musculoskeletal Disorders, 2020-2030
13.3.4.11. In Silico Drug Discovery Services Market for Large Molecules: Share of Neurological Disorders, 2020-2030
13.3.4.12. In Silico Drug Discovery Services Market for Large Molecules: Share of Oncological Disorders 2020-2030
13.3.4.13. In Silico Drug Discovery Services Market for Large Molecules: Share of Respiratory Disorders, 2020-2030
13.3.4.13. In Silico Drug Discovery Services Market for Large Molecules: Share of Skin Disorders, 2020-2030
13.3.4.14. In Silico Drug Discovery Services Market for Large Molecules: Share of Urogenital Disorders, 2020-2030
13.3.4.15. In Silico Drug Discovery Services Market for Large Molecules: Share of Others, 2020-2030
13.3.5. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, 2020-2030
13.3.5.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Industry Players, 2020-2030
13.3.5.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Non-Industry Players, 2020-2030
13.3.6. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, 2020-2030
13.3.6.1. In Silico Drug Discovery Services Market for Large Molecules: Share of North America, 2020-2030
13.3.6.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of US, 2020-2030
13.3.6.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Canada, 2020-2030
13.3.6.2. In Silico Drug Discovery Services Market for Large Molecules: Share in Europe, 2020-2030
13.3.6.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share in Germany, 2020-2030
13.3.6.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share in France, 2020-2030
13.3.6.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share in the UK, 2020-2030
13.3.6.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share in Italy, 2020-2030
13.3.6.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share in Spain, 2020-2030
13.3.6.2.6. In Silico Drug Discovery Services Market for Large Molecules: Share in Rest of Europe, 2020-2030
13.3.6.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Asia-Pacific and Rest of the World, 2020-2030
13.3.6.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share in China, 2020-2030
13.3.6.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share in India, 2020-2030
13.3.6.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Japan, 2020-2030
14. IN SILICO TOOLS AND UPCOMING TRENDS IN DRUG DISCOVERY
14.1. Chapter Overview
14.2. Owing to Potential Cost and Time-related Benefits, Outsourcing of Drug Discovery Operations is Expected to Increase in the Future
14.3. Technological Advancements are Likely to Revolutionize the Current Drug Discovery Processes
14.3.1. Integration of Artificial Intelligence in the Drug Discovery Process is Expected to Improve the Overall Efficiency and Productivity
14.3.2. Increased Adoption of Cloud Based Technology Platforms is Anticipated to Enhance the Scalability and Flexibility of the Drug Discovery Process
14.3.3. Rising Interest in Use of Force Fields for In Silico Drug Discovery
14.4. Concluding Remarks
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. ProSciens
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Edelmiro Moman, Founder and Chief Executive Officer
15.3. Conifer Point Pharmaceuticals
15.3.1. Company Snapshot
15.3.2. Interview Transcript: John L Kulp, Chief Executive Officer and Chief Technical Officer
15.4. Evotec
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Mark Whittaker, Senior Vice President, Drug Discovery
15.5. Candidum
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Sven Benson, Founder
16. APPENDIX I: TABULATED DATA
17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
18. APPENDIX III: NON-COMPUTATIONAL METHODS FOR DRUG DISCOVERY
LIST OF FIGURES
Figure 3.1. Drug Discovery and Development Timeline
Figure 3.2. Historical Evolution of Computational Drug Discovery Approaches
Figure 3.3. Steps Involved in the Virtual Drug Discovery Process
Figure 3.4. Comparison of Traditional and In Silico Drug Discovery Approaches
Figure 3.5. Classification of In Silico Drug Discovery Approaches
Figure 3.6. Flowchart of the In Silico Drug Discovery Approach
Figure 3.7. In Silico Drug Discovery Service Map
Figure 3.8. Advantages of using In Silico Drug Discovery Services
Figure 3.9. Types of Large Molecule Drugs
Figure 4.1. In Silico Drug Discovery Services for Large Molecules: Distribution by Year of Establishment
Figure 4.2. In Silico Drug Discovery Services for Large Molecules: Distribution by Company Size
Figure 4.3. In Silico Drug Discovery Services for Large Molecules: Distribution by Location of Headquarters
Figure 4.4. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Business Model
Figure 4.5. In Silico Drug Discovery Services for Large Molecules: Distribution by Drug Discovery Steps
Figure 4.6. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Large Molecule
Figure 4.7. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Antibody
Figure 4.8. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Protein
Figure 4.9. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of In Silico Approach Used
Figure 4.10. In Silico Drug Discovery Services for Large Molecules: Distribution by Types of In Silico Services Offered
Figure 5.1. Logo Landscape: Distribution by Company Size and Location of Headquarters
Figure 5.2. Tree Map Representation: Distribution by Company Size and Drug Discovery Steps
Figure 5.3. World Map Representation: Regional Analysis of Outsourcing Activity
Figure 5.4. Grid Representation: Distribution by Type of Large Molecule, Designing Approach Used and Type of Clientele
Figure 6.1. BioDuro: In Silico-based Service Portfolio
Figure 6.2. BioDuro: Peer Group Benchmark Comparison
Figure 6.3. Creative Biostructure: In Silico-based Service Portfolio
Figure 6.4. Creative Biostructure: Peer Group Benchmark Comparison
Figure 6.5. GenScript: In Silico-based Service Portfolio
Figure 6.6. GenScript: Peer Group Benchmark Comparison
Figure 6.7. LakePharma: In Silico-based Service Portfolio
Figure 6.8. LakePharma: Peer Group Benchmark Comparison
Figure 6.9. Abzena: In Silico-based Service Portfolio
Figure 6.10. Abzena: Company Benchmarking Output
Figure 6.11. BioNTech: In Silico-based Service Portfolio
Figure 6.12. BioNTech: Peer Group Benchmark Comparison
Figure 6.13. Sygnature Discovery: In Silico-based Service Portfolio
Figure 6.14. Sygnature Discovery: Peer Group Benchmark Comparison
Figure 6.15. ChemPartner: In Silico-based Service Portfolio
Figure 6.16. ChemPartner: Peer Group Benchmark Comparison
Figure 6.17. Sundia MediTech: In Silico-based Service Portfolio
Figure 6.18. Sundia MediTech: Peer Group Benchmark Comparison
Figure 6.19. Viva Biotech: In Silico-based Service Portfolio
Figure 6.20. Viva Biotech: Peer Group Benchmark Comparison
Figure 7.1. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
Figure 7.2. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
Figure 7.3. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World
Figure 8.1. In Silico Drug Discovery Service Providers for Antibodies: 3D Bubble Representation
Figure 8.2. In Silico Drug Discovery Service Providers for Cell Therapies: 3D Bubble Representation
Figure 8.3. In Silico Drug Discovery Service Providers for Gene Therapies: 3D Bubble Representation
Figure 8.4. In Silico Drug Discovery Service Providers for Nucleic Acids: 3D Bubble Representation
Figure 8.5. In Silico Drug Discovery Service Providers for Peptides: 3D Bubble Representation
Figure 8.6. In Silico Drug Discovery Service Providers for Proteins: 3D Bubble Representation
Figure 8.7. In Silico Drug Discovery Service Providers for Vectors 3D Bubble Representation
Figure 9.1. In Silico Drug Discovery Service Providers: Popular Strategies or Business Models
Figure 10.1. Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval (2005-2019)
Figure 10.2. Small Molecules versus Large Molecules: Comparison of Key Characteristics
Figure 10.3. Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 11.1. Survey Insights: Distribution of Respondents by Year of Establishment of Company
Figure 11.2. Survey Insights: Distribution of Respondents by Company Size
Figure 11.3. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Continent-Wise)
Figure 11.4. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Figure 11.5. Survey Insights: Distribution by Designation and Seniority Level of Respondents
Figure 11.6. Survey Insights: Distribution by Drug Discovery Steps
Figure 11.7. Survey Insights: Distribution by Type of Large Molecule
Figure 11.8. Survey Insights: Distribution by In Silico-based Service Portfolio
Figure 11.9. Survey Insights: Distribution by Likely Adoption of In Silico Tools
Figure 11.10. Survey Insights: Distribution by Current Market Opportunity
Figure 11.11. Survey Insights: Distribution by Likely Growth Rate
Figure 11.12. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
Figure 12.1. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery: Growth Scenarios
Figure 12.2. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, 2020-2030 (USD Billion)
Figure 13.1. In Silico Drug Discovery Services Market for Large Molecules: Methodology and Key Assumptions
Figure 13.2. Overall In Silico Drug Discovery Services Market for Large Molecules, 2020-2030 (USD Million)
Figure 13.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, 2020 and 2030 (USD Million)
Figure 13.4. In Silico Drug Discovery Services Market for Large Molecules for Target Identification, 2020-2030 (USD Million)
Figure 13.5. In Silico Drug Discovery Services Market for Large Molecules for Target Validation, 2020-2030 (USD Million)
Figure 13.6. In Silico Drug Discovery Services Market for Large Molecules for Hit Generation, 2020-2030 (USD Million)
Figure 13.7. In Silico Drug Discovery Services Market for Large Molecules for Hit-to-Lead, 2020-2030 (USD Million)
Figure 13.8. In Silico Drug Discovery Services Market for Large Molecules for Lead Optimization, 2020-2030 (USD Million)
Figure 13.9. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, 2020 and 2030 (USD Million)
Figure 13.10. In Silico Drug Discovery Services Market for Large Molecules for Antibodies, 2020-2030 (USD Million)
Figure 13.11. In Silico Drug Discovery Services Market for Large Molecules for Proteins, 2020-2030 (USD Million)
Figure 13.12. In Silico Drug Discovery Services Market for Large Molecules for Peptides, 2020-2030 (USD Million)
Figure 13.13. In Silico Drug Discovery Services Market for Large Molecules for Nucleic Acid, 2020-2030 (USD Million)
Figure 13.14. In Silico Drug Discovery Services Market for Large Molecules for Vectors, 2020-2030 (USD Million)
Figure 13.15. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, 2020 and 2030 (USD Million)
Figure 13.16. In Silico Drug Discovery Services Market for Large Molecules for Small Companies, 2020-2030 (USD Million)
Figure 13.17. In Silico Drug Discovery Services Market for Large Molecules for Mid-sized Companies, 2020-2030 (USD Million)
Figure 13.18. In Silico Drug Discovery Services Market for Large Molecules for Large Companies, 2020-2030 (USD Million)
Figure 13.19. In Silico Drug Discovery Services Market for Large Molecules: Market Attractiveness Analysis by Type of Therapeutic Area, 2020 and 2030 (USD Million)
Figure 13.20. In Silico Drug Discovery Services Market for Large Molecules for Autoimmune Disorders, 2020-2030 (USD Million)
Figure 13.21. In Silico Drug Discovery Services Market for Large Molecules for Blood Disorders, 2020-2030 (USD Million)
Figure 13.22. In Silico Drug Discovery Services Market for Large Molecules for Cardiovascular Disorders, 2020-2030 (USD Million)
Figure 13.23. In Silico Drug Discovery Services Market for Large Molecules for Gastrointestinal and Digestive Disorders, 2020-2030 (USD Million)
Figure 13.24. In Silico Drug Discovery Services Market for Large Molecules for Hormonal Disorders, 2020-2030 (USD Million)
Figure 13.25. In Silico Drug Discovery Services Market for Large Molecules for HIV / AIDS, 2020-2030 (USD Million)
Figure 13.26. In Silico Drug Discovery Services Market for Large Molecules for Infectious Diseases, 2020-2030 (USD Million)
Figure 13.27. In Silico Drug Discovery Services Market for Large Molecules for Metabolic Disorders, 2020-2030 (USD Million)
Figure 13.28. In Silico Drug Discovery Services Market for Large Molecules for Mental Disorders, 2020-2030 (USD Million)
Figure 13.29. In Silico Drug Discovery Services Market for Large Molecules for Musculoskeletal Disorders, 2020-2030 (USD Million)
Figure 13.30. In Silico Drug Discovery Services Market for Large Molecules for Neurological Disorders, 2020-2030 (USD Million)
Figure 13.31. In Silico Drug Discovery Services Market for Large Molecules for Oncological Disorders, 2020-2030 (USD Million)
Figure 13.32. In Silico Drug Discovery Services Market for Large Molecules for Respiratory Disorders, 2020-2030 (USD Million)
Figure 13.33. In Silico Drug Discovery Services Market for Large Molecules for Skin Disorders, 2020-2030 (USD Million)
Figure 13.34. In Silico Drug Discovery Services Market for Large Molecules for Urogenital Disorders, 2020-2030 (USD Million)
Figure 13.35. In Silico Drug Discovery Services Market for Large Molecules for Others, 2020-2030 (USD Million)
Figure 13.36. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, 2020 and 2030 (USD Million)
Figure 13.37. In Silico Drug Discovery Services Market for Large Molecules for Industry Players, 2020-2030 (USD Million)
Figure 13.38. In Silico Drug Discovery Services Market for Large Molecules for Non-Industry Players, 2020-2030 (USD Million)
Figure 13.39. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, 2020 and 2030 (USD Million)
Figure 13.40. In Silico Drug Discovery Services Market for Large Molecules in North America, 2020 and 2030 (USD Million)
Figure 13.41. In Silico Drug Discovery Services Market for Large Molecules in the US, 2020- 2030 (USD Million)
Figure 13.42. In Silico Drug Discovery Services Market for Large Molecules in Canada, 2020-2030 (USD Million)
Figure 13.43. In Silico Drug Discovery Services Market for Large Molecules in Europe, 2020 and 2030 (USD Million)
Figure 13.44. In Silico Drug Discovery Services Market for Large Molecules in Germany, 2020-2030 (USD Million)
Figure 13.45. In Silico Drug Discovery Services Market for Large Molecules in France, 2020-2030 (USD Million)
Figure 13.46. In Silico Drug Discovery Services Market for Large Molecules in the UK, 2020-2030 (USD Million)
Figure 13.47. In Silico Drug Discovery Services Market for Large Molecules in Italy, 2020-2030 (USD Million)
Figure 13.48. In Silico Drug Discovery Services Market for Large Molecules in Spain, 2020-2030 (USD Million)
Figure 13.49. In Silico Drug Discovery Services Market for Large Molecules in Rest of Europe, 2020-2030 (USD Million)
Figure 13.50. In Silico Drug Discovery Services Market for Large Molecules in Asia-Pacific and Rest of the World, 2020 and 2030 (USD Million)
Figure 13.51. In Silico Drug Discovery Services Market for Large Molecules in China, 2020-2030 (USD Million)
Figure 13.52. In Silico Drug Discovery Services Market for Large Molecules in India, 2020-2030 (USD Million)
Figure 13.53. In Silico Drug Discovery Services Market for Large Molecules in Japan, 2020-2030 (USD Million)
Figure 14.1. Upcoming Trends in Drug Discovery: Future Growth Opportunities
LIST OF TABLES
Table 4.1. In Silico Drug Discovery Service Providers for Large Molecules: List of Industry Players
Table 4.2. In Silico Drug Discovery Services for Large Molecules: Information on Drug Discovery Steps
Table 4.3. In Silico Drug Discovery Service Providers for Large Molecules: Information on Type of In Silico Approach
Table 4.4. In Silico Drug Discovery Service Providers for Large Molecules: Information on Type of Clienetle
Table 4.5. In Silico Drug Discovery Services for Large Molecules: Information on Type of Large Molecule
Table 4.6. In Silico Drug Discovery Services for Large Molecules: Information on In Silico-based Service Offerings
Table 4.7. In Silico Drug Discovery Services for Large Molecules: Additional Information
Table 4.8. In Silico Drug Discovery Services: List of Software / Technologies
Table 4.9. In Silico Drug Discovery Services: List of Consulting and Training Service Providers
Table 6.1. In Silico Service Providers: List of Companies Profiled
Table 6.2. BioDuro: Key Highlights
Table 6.3. BioDuro: List of Funding Instances and Investors
Table 6.4. BioDuro: Recent Developments and Future Outlook
Table 6.5. Creative Biostructure: Key Highlights
Table 6.6. Creative Biostructure: List of Funding Instances and Investors
Table 6.7. Creative Biostructure: Recent Developments and Future Outlook
Table 6.8. GenScript: Key Highlights
Table 6.9. GenScript: List of Funding Instances and Investors
Table 6.10. GenScript: Recent Developments and Future Outlook
Table 6.11. LakePharma: Key Highlights
Table 6.12. LakePharma: List of Funding Instances and Investors
Table 6.13. LakePharma: Recent Developments and Future Outlook
Table 6.14. Abzena: Key Highlights
Table 6.15. Abzena: List of Funding Instances and Investors
Table 6.16. Abzena: Recent Developments and Future Outlook
Table 6.17. BioNTech: Key Highlights
Table 6.18. BioNTech: List of Funding Instances and Investors
Table 6.19. BioNTech: Recent Developments and Future Outlook
Table 6.20. Sygnature Discovery: Key Highlights
Table 6.21. Sygnature Discovery: List of Funding Instances and Investors
Table 6.22. Sygnature Discovery: Recent Developments and Future Outlook
Table 6.23. ChemPartner: Key Highlights
Table 6.24. ChemPartner: Recent Developments and Future Outlook
Table 6.25. Sundia MediTech: Key Highlights
Table 6.26. Sundia MediTech: List of Funding Instances and Investors
Table 6.27. Sundia MediTech: Recent Developments and Future Outlook
Table 6.28. Viva Biotech: Key Highlights
Table 6.29. Viva Biotech: List of Funding Instances and Investors
Table 6.30. Viva Biotech: Recent Developments and Future Outlook
Table 10.1. Comparison of Strengths and Weaknesses of Small Molecules and Large Molecules
Table 10.2. Comparison of Development Characteristics of Small Molecules and Large Molecules
Table 10.3. Challenges in the Discovery of Different Types of Large Molecules
Table 11.1. Survey Insights: Overview of Respondents
Table 11.2. Survey Insights: Designation and Seniority Levels
Table 11.3. Survey Insights: Distribution by Drug Discovery Steps
Table 11.4. Survey Insights: Distribution by Type of Large Molecule
Table 11.5. Survey Insights: Distribution by In Silico-based Service Portfolio
Table 11.6. Survey Insights: Distribution by Likely Adoption of In Silico Tools
Table 11.7. Survey Insights: Distribution by Current Market Opportunity
Table 11.8. Survey Insights: Distribution by Likely Growth Rate
Table 11.9. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
Table 12.1. Likely Cost Reduction using In Silico Services for Large Molecules
Table 12.2 Drug Discovery Steps: Key Parameters
Table 14.1. Companies Offering Artificial Intelligence and In Silico Services
Table 14.2. Companies Offering Cloud Computing Platforms and In Silico Services
Table 15.1. Conifer Point Pharmaceuticals: Company Snapshot
Table 15.2. candidum: Company Snapshot
Table 15.3. Evotec: Company Snapshot
Table 15.4. ProSciens: Company Snapshot
Table 16.1. In Silico Drug Discovery Services for Large Molecules: Distribution by Year of Establishment
Table 16.2. In Silico Drug Discovery Services for Large Molecules: Distribution by Company Size
Table 16.3. In Silico Drug Discovery Services for Large Molecules: Distribution by Location of Headquarters
Table 16.4. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Business Model
Table 16.5. In Silico Drug Discovery Services for Large Molecules: Distribution by Drug Discovery Steps
Table 16.6. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Large Molecule
Table 16.7. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Antibody
Table 16.8. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Protein
Table 16.9. In Silico Drug Discovery Services for Large Molecules: Distribution by Type of Designing Approach Used
Table 16.10. In Silico Drug Discovery Services for Large Molecules: Distribution by In Silico Service Offering
Table 16.11. Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval (2005 - 2019)
Table 16.12. Survey Insights: Distribution of Respondents by Year of Establishment of Company
Table 16.13. Survey Insights: Distribution of Respondents by Employee Size
Table 16.14. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Continent-Wise)
Table 16.15. Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
Table 16.16. Survey Insights: Distribution by Designation and Seniority Level of Respondents
Table 16.17. Survey Insights: Distribution by Drug Discovery Steps
Table 16.18. Survey Insights: Distribution by Type of Large Molecule
Table 16.19. Survey Insights: Distribution by In Silico-based Service Portfolio
Table 16.20. Survey Insights: Distribution by Likely Adoption of In Silico Tools
Table 16.21. Survey Insights: Distribution by Current Market Opportunity
Table 16.22. Survey Insights: Distribution by Likely Growth Rate
Table 16.23. Survey Insights: Distribution by Likely Cost Reduction using In Silico Tools in Large Molecule Drug Discovery
Table 16.24. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, 2020-2030 (USD Billion)
Table 16.25. Overall In Silico Drug Discovery Services Market for Large Molecules, 2020-2030 (USD Million)
Table 16.26. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, 2020 and 2030 (USD Million)
Table 16.27. In Silico Drug Discovery Services Market for Large Molecules for Target Identification, 2020-2030 (USD Million)
Table 16.28. In Silico Drug Discovery Services Market for Large Molecules for Target Validation, 2020-2030 (USD Million)
Table 16.29. In Silico Drug Discovery Services Market for Large Molecules for Hit Generation, 2020-2030 (USD Million)
Table 16.30. In Silico Drug Discovery Services Market for Large Molecules for Hit-to-Lead,- 2020-2030 (USD Million)
Table 16.31. In Silico Drug Discovery Services Market for Large Molecules for Lead Optimization, 2020-2030 (USD Million)
Table 16.32. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, 2020 and 2030 (USD Million)
Table 16.33. In Silico Drug Discovery Services Market for Large Molecules for Antibodies, 2020-2030 (USD Million)
Table 16.34. In Silico Drug Discovery Services Market for Large Molecules for Proteins, 2020-2030 (USD Million)
Table 16.35. In Silico Drug Discovery Services Market for Large Molecules for Peptides, 2020-2030 (USD Million)
Table 16.36. In Silico Drug Discovery Services Market for Large Molecules for Nucleic Acid, 2020-2030 (USD Million)
Table 16.37. In Silico Drug Discovery Services Market for Large Molecules for Vectors, 2020-2030 (USD Million)
Table 16.38. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, 2020 and 2030 (USD Million)
Table 16.39. In Silico Drug Discovery Services Market for Large Molecules for Small Companies, 2020-2030 (USD Million)
Table 16.40. In Silico Drug Discovery Services Market for Large Molecules for Mid-sized Companies, 2020-2030 (USD Million)
Table 16.41. In Silico Drug Discovery Services Market for Large Molecules for Large Companies, 2020-2030 (USD Million)
Table 16.42. In Silico Drug Discovery Services Market for Large Molecules for Autoimmune Disorders, 2020-2030 (USD Million)
Table 16.43. In Silico Drug Discovery Services Market for Large Molecules for Blood Disorders, 2020-2030 (USD Million)
Table 16.44. In Silico Drug Discovery Services Market for Large Molecules for Cardiovascular Disorders, 2020-2030 (USD Million)
Table 16.45. In Silico Drug Discovery Services Market for Large Molecules for Gastrointestinal and Digestive Disorders, 2020-2030 (USD Million)
Table 16.46. In Silico Drug Discovery Services Market for Large Molecules for Hormonal Disorders, 2020-2030 (USD Million)
Table 16.47. In Silico Drug Discovery Services Market for Large Molecules for HIV / AIDS, 2020-2030 (USD Million)
Table 16.48. In Silico Drug Discovery Services Market for Large Molecules for Infectious Diseases, 2020-2030 (USD Million)
Table 16.49. In Silico Drug Discovery Services Market for Large Molecules for Metabolic Disorders, 2020-2030 (USD Million)
Table 16.50. In Silico Drug Discovery Services Market for Large Molecules for Mental Disorders, 2020-2030 (USD Million)
Table 16.51. In Silico Drug Discovery Services Market for Large Molecules for Musculoskeletal Disorders, 2020-2030 (USD Million)
Table 16.52. In Silico Drug Discovery Services Market for Large Molecules for Neurological Disorders, 2020-2030 (USD Million)
Table 16.53. In Silico Drug Discovery Services Market for Large Molecules for Oncological Disorders, 2020-2030 (USD Million)
Table 16.54. In Silico Drug Discovery Services Market for Large Molecules for Respiratory Disorders, 2020-2030 (USD Million)
Table 16.55. In Silico Drug Discovery Services Market for Large Molecules for Skin Disorders, 2020-2030 (USD Million)
Table 16.56. In Silico Drug Discovery Services Market for Large Molecules for Urogenital Disorders, 2020-2030 (USD Million)
Table 16.57. In Silico Drug Discovery Services Market for Large Molecules for Others, 2020-2030 (USD Million)
Table 16.58. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, 2020 and 2030 (USD Million)
Table 16.59. In Silico Drug Discovery Services Market for Large Molecules for Industry Players, 2020-2030 (USD Million)
Table 16.60. In Silico Drug Discovery Services Market for Large Molecules for Non-Industry Players, 2020-2030 (USD Million)
Table 16.61. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, 2020 and 2030 (USD Million)
Table 16.62. In Silico Drug Discovery Services Market for Large Molecules in North America, 2020 and 2030 (USD Million)
Table 16.63. In Silico Drug Discovery Services Market for Large Molecules in the US, 2020- 2030 (USD Million)
Table 16.64. In Silico Drug Discovery Services Market for Large Molecules in Canada, 2020-2030 (USD Million)
Table 16.65. In Silico Drug Discovery Services Market for Large Molecules in Europe, 2020 and 2030 (USD Million)
Table 16.66. In Silico Drug Discovery Services Market for Large Molecules in Germany, 2020-2030 (USD Million)
Table 16.67. In Silico Drug Discovery Services Market for Large Molecules in France, 2020-2030 (USD Million)
Table 16.68. In Silico Drug Discovery Services Market for Large Molecules in the UK, 2020-2030 (USD Million)
Table 16.69. In Silico Drug Discovery Services Market for Large Molecules in Italy, 2020-2030 (USD Million)
Table 16.70. In Silico Drug Discovery Services Market for Large Molecules in Spain, 2020-2030 (USD Million)
Table 16.71. In Silico Drug Discovery Services Market for Large Molecules in Rest of Europe, 2020-2030 (USD Million)
Table 16.72. In Silico Drug Discovery Services Market for Large Molecules in Asia-Pacific and Rest of the World, 2020 and 2030 (USD Million)
Table 16.73. In Silico Drug Discovery Services Market for Large Molecules in China, 2020-2030 (USD Million)
Table 16.74. In Silico Drug Discovery Services Market for Large Molecules in India, 2020-2030 (USD Million)
Table 16.75. In Silico Drug Discovery Services Market for Large Molecules in Japan, 2020-2030 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook